DGAP-News: Medios AG / Key word(s): Forecast/Capital Increase
12.03.2018 / 11:29
The issuer is solely responsible for the content of this announcement.
Medios AG expects significant increase in sales and earnings in 2018 financial year
Berlin, 12 March 2018 – Medios AG (‘Medios’), one of the leading Specialty Pharma Companies in Germany, expects a significant increase in sales and earnings in the 2018 financial year. Accordingly, the Management Board expects Group sales in the amount of around 320 million euros (IFRS) and Group earnings before taxes (EBT*) in the amount of around 11 million euros (IFRS)**. This represents considerable growth of 26 per cent and 37 per cent respectively compared to the preliminary figures already published for the 2017 financial year totalling 253 million euros (IFRS) and 8.0 million euros (IFRS) respectively.
The reasons for the expected increases in sales and earnings in the 2018 financial year are, in particular, the planned gaining of market shares as well as the further expansion of the partner network and the product offering. Additionally, the forecast takes into consideration the planned growth of the patient-specific preparations segment through the expansion of the manufacturing facilities for non-cytostatic products. For this purpose, the company intends to take over substantial operating units of BerlinApotheke Schneider & Oleski oHG (“BerlinApotheke”). The acquisition will be carried out without the expenditure of cash by means of a capital increase in kind in exchange for new shares issued to the contributing party, Mr Manfred Schneider, CEO of Medios AG and co-owner of BerlinApotheke. The new shares shall be introduced to trading on the regulated market of the Frankfurt Stock Exchange (General Standard). The required approval of the boards and the relevant authorities is expected over the coming weeks.
Matthias Gärtner, CFO of Medios AG: ‘With the takeover of the operating units and the expansion of the manufacturing facilities for non-cytostatic products, we can continue the expansion of our dynamically growing segment for patient-specific preparations, thereby taking us one step closer to achieving our goal of becoming the leading provider of Specialty Pharma solutions in Germany. The operating units are expected to be fully integrated into the Medios Group within the 2018 financial year and to begin production as of June 2018. Thereby, they will unfold their full potential from 2019 and then make significant contributions to EBT.’
* EBT is defined as net earnings before income taxes.
About Medios AG
Medios AG is Germany’s first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.
12.03.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 30 232 566 – 800|
|Fax:||030 / 8321 8377|
|Listed:||Regulated Market in Frankfurt (General Standard), Hamburg; Regulated Unofficial Market in Dusseldorf|
|End of News||DGAP News Service|